Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
Circulation|August 1, 1992
Electrocardiographic body surface mapping in patients with ventricular tachycardia. Assessment of utility in the identification of effective pharmacological therapyL B Mitchell, C L Hubley-Kozey, E R Smith, et al.
Natural Toxins|January 1, 1996
Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisinsR T Riley, E Wang, J J Schroeder, et al.
Urology|January 14, 1998
Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy aloneC L Coogan, R S Foster, R G Rowland, et al.
Journal of Environmental Pathology and Toxicology|June 1, 1980
Carcinogenesis bioassay of acetamide, hexanamide, adipamide, urea and P-tolylurea in mice and ratsR W Fleischman, J R Baker, M Hagopian, et al.
Nucleic Acids Research|June 5, 1998
Cloning of Drosophila GCN5: conserved features among metazoan GCN5 family membersE R Smith, J M Belote, R L Schiltz, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 16, 2001
Ventricular interaction and external constraint account for decreased stroke work during volume loading in CHFT D Moore, M P Frenneaux, R Sas, et al.
AJNR. American Journal of Neuroradiology|December 17, 2009
A novel association between RASA1 mutations and spinal arteriovenous anomaliesR Thiex, J B Mulliken, N Revencu, et al.
Circulation|May 1, 1995
Regional left ventricular systolic function in relation to the cavity geometry in patients with chronic right ventricular pressure overload. A three-dimensional tagged magnetic resonance imaging studyS J Dong, A P Crawley, J H MacGregor, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|April 25, 2025
Outcome assessment in veterinary pain studies: a pain in animals workshop (PAW) perspectiveD C Brown, J Coetzee, M Gill, et al.
JTO Clinical and Research Reports|January 1, 2024
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With AtezolizumabKatherine E R Smith, Stephanie L Pritzl, Wei Yu, et al.
Pageof 32